Abstract
Busulfan (BU) is utilized frequently for myeloablation in children undergoing hematopoietic stem cell transplantation (HSCT). A 7-10% incidence of seizures has been reported for patients receiving BU without any anti-convulsant prophylaxis. The PK profile of Levetiracetam is favorable as an anti-convulsant in this setting. This study compared levetiracetam and fosphenytoin during BU, examining the effect on busulfan levels, efficiency of administration (cost, nursing time, drug compatibility), and efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
